Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

@article{Eymard2007RandomizedPI,
  title={Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.},
  author={J. C. Eymard and Frank Priou and Alain Zannetti and Alain Mure Ravaud and Daniel Lepill{\'e} and Pierre Kerbrat and Patricia F G{\'o}mez and Bernard Paule and Dominique Genet and Patrice H{\'e}rait and Evelyne B Ecstein-Fra{\"i}ss{\'e} and Florence Joly},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2007},
  volume={18 6},
  pages={1064-70}
}
BACKGROUND Docetaxel (Taxotere)-based regimens are the new standard therapy in advanced hormone-refractory prostate cancer (HRPC). A synergistic activity has been shown with docetaxel in combination with estramustine in vitro; however, the benefit of this combination remains controversial in clinical practice. We assessed the activity and safety of docetaxel alone and docetaxel-estramustine in HRPC. PATIENTS AND METHODS Patients (n = 92) with metastatic HRPC and rising prostate-specific… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

The evolution of chemotherapy for the treatment of prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Similar Papers

Loading similar papers…